(Q36946766)

17 August 2017

1 reference

title

Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies (English)

1 reference

17 August 2017

Judith E Karp

1

1 reference

PubMed ID

17882662

17 August 2017

Jeffrey E Lancet

series ordinal

2

1 reference

17 August 2017

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

25

1 reference

17 August 2017

6

1 reference

17 August 2017

484-494

1 reference

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

17 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Proteins regulating Ras and its relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Function and regulation of ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Mechanisms and consequences of activation of protein kinase B/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Acute myelogenous leukemia and aging. Clinical interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Interactions among proteins involved in bud-site selection and bud-site assembly in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

Protein kinase A- and protein kinase C-regulated interaction of plectin with lamin B and vimentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

A mitotic lamin B matrix induced by RanGTP required for spindle assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701359437

10.1080/07357900701359437

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17882662